Alpha-Ketoglutarate Tracked 1.8 Years Younger; 370 Drugs Flagged for Aging [Best Read]
Plus brain cells that tripled Alzheimer's risk, the 41-trial verdict on lowering biological age, and a human-only aging RNA.
In my work as a Silicon Valley based startup executive and longevity researcher, I track the gap between what the labs are publishing and what's actually worth adding to your protocol. Here's what stood out this week — with the numbers that matter.
Alpha-Ketoglutarate Users Tracked 1.8 Years Younger Across 4,200 People [NutraIngredients]
Researchers at the National University of Singapore cross-referenced 84 supplements against saliva-based epigenetic age tests from more than 4,200 people. Delayed-release calcium alpha-ketoglutarate (the Rejuvant formulation, which also carries vitamins A and D3) stood out: its 143 users averaged 1.8 years lower biological age than non-users, and the gap held after adjusting for weight, exercise, and alcohol. The honest caveat is that the longitudinal slice of just 26 people showed no significant change over time, so this is a strong correlation, not proof. AKG is a citric-acid-cycle molecule that declines with age and has extended lifespan in flies and mice. For your protocol: AKG remains one of the better-evidenced longevity supplements, but treat 1.8 years as an association to watch, not a guarantee.
Screening 6,442 Drugs, a Network Map Flagged 370 That May Target Aging [Lifespan.io]
A Northeastern and Harvard team led by network scientist Albert-Laszlo Barabasi mapped 6,442 approved drugs onto the Hallmarks of Aging using a human protein-interaction network of over 500,000 links. Their SHARP pipeline flagged 370 compounds close enough to a hallmark to plausibly perturb it, including 83 network drugs that act only indirectly. As validation, all 8 drugs that extended mouse lifespan in the rigorous Interventions Testing Program scored positive, while fewer than half of the failures did. Strikingly, aspirin mapped to 6 hallmarks and dasatinib to 5, but rapamycin touched only 1. For your protocol: this is a candidate-generation tool, not a prescription, but it argues that a drug's breadth across aging hallmarks may matter more than its reputation.
Fast-Aging Brain Cells Tripled Alzheimer's Risk Across 60,000 People [Lifespan.io]
Stanford's Tony Wyss-Coray and colleagues built machine-learning clocks for more than 40 individual cell types by reading their protein signatures in blood, then tested them across roughly 60,000 people. Aging was strikingly uneven: 35 percent of people had no extreme age gaps in any cell type, while 1.5 percent showed extreme aging in ten or more. The payoff was in prediction. Among APOE4 homozygotes, those with rapidly aging astrocytes were nearly three times as likely to develop Alzheimer's, and accelerated skeletal-muscle-cell aging flagged ALS more than three years before diagnosis. For your protocol: a single whole-body biological age number is getting too blunt to act on, and organ-by-organ aging is where useful diagnostics are heading.
41 Human Trials Ranked What Lowers Biological Age; Rapamycin Missed [Fight Aging]
A new systematic review pooled 41 human studies that measured next-generation epigenetic clocks, the kind most tied to mortality, before and after an intervention. The approaches that consistently lowered epigenetic age were unglamorous: exercise, a plant-rich diet, caloric restriction, omega-3s, a multivitamin-mineral, the GLP-1 drug semaglutide, umbilical-cord plasma, and the statin pitavastatin. More provocative were the misses: nicotinamide riboside, rapamycin, and senolytics showed no detectable effect on these clocks, and plasmapheresis actually accelerated measured aging. For your protocol: the boring basics still carry the strongest human epigenetic data, and several buzzy interventions do not yet move these clocks, though a null clock result is not the same as no benefit.
A Human-Only RNA That Mice Lack Drove Senescence in 7 Tissues [Aging Cell]
Human genomes carry roughly three times more long non-coding RNA than mice, and this study zeroed in on one strand, LINC01021, that has no mouse equivalent. Its expression shifted with age across 7 tissues, and forcing it higher pushed human fibroblasts into senescence while silencing it protected them. Mechanistically it suppresses a protein called RBMX, which in turn raises the senescence driver p53. When researchers knocked the human gene into mice, the animals grew frail earlier, with weaker grip strength and more inflammation. For your protocol: nothing to take here yet, but it is a sharp reminder that mouse studies can miss human-specific aging drivers entirely, so stay skeptical when a rodent result is sold as a finished human answer.
Blocking One Protein Cut 3 Kidney-Failure Markers in 4 Weeks [Fight Aging]
A monoclonal antibody called AD-NP1, already cleared by the FDA for a Phase 1 heart-repair trial, turns out to help a second organ. It blocks ENPP1, a protein that injured tissue releases to stall energy production and healing. In mice given kidney-damaging drugs, blocking ENPP1 sped repair and reduced scarring, and after 4 weeks the three standard markers of kidney failure (creatinine, BUN, and cystatin C) were sharply lower than in controls. For your protocol: this is early animal work, but a regeneration approach that already has a human safety trial underway is worth tracking, especially since kidney function is an underrated longevity lever.